These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 21385444

  • 1. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, Wani AA.
    Mol Cancer; 2011 Mar 08; 10():24. PubMed ID: 21385444
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.
    Cancer Res; 2015 Feb 15; 75(4):628-34. PubMed ID: 25634215
    [Abstract] [Full Text] [Related]

  • 4. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ, Yu C, Yang Z, He JL, Chen WJ, Yin J, Li WM, Liu HT, Wang YX.
    Mol Med Rep; 2011 Feb 15; 4(5):985-92. PubMed ID: 21687949
    [Abstract] [Full Text] [Related]

  • 5. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
    Cancer Res; 2003 Mar 15; 63(6):1311-6. PubMed ID: 12649192
    [Abstract] [Full Text] [Related]

  • 6. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L, Liu K, Wang X, Chen H, Zhou J, Wu X, Liu T, Yang Y, Yang X, Cui D, Song G, Wang J, Lei J.
    Int J Biochem Cell Biol; 2018 Jul 15; 100():54-60. PubMed ID: 29768183
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P, Li J, Chen YC, Qian H, Chen YJ, Su JY, Wu M, Lan T.
    Cell Oncol (Dordr); 2016 Dec 15; 39(6):511-522. PubMed ID: 27473273
    [Abstract] [Full Text] [Related]

  • 11. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P, Eichhorn JM, Suparman E, Bückreiß N, Cinatl J, Michaelis M, Bendas G.
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec 15; 1870(8):167448. PubMed ID: 39117290
    [Abstract] [Full Text] [Related]

  • 12. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.
    Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N.
    Sci Rep; 2018 Sep 04; 8(1):13207. PubMed ID: 30181600
    [Abstract] [Full Text] [Related]

  • 13. Functional profiling of nucleotide Excision repair in breast cancer.
    Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H, Kochupurakkal B, D'Andrea AD, Shapiro GI, Lazaro JB, Mouw KW.
    DNA Repair (Amst); 2019 Oct 04; 82():102697. PubMed ID: 31499327
    [Abstract] [Full Text] [Related]

  • 14. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
    Ferry KV, Hamilton TC, Johnson SW.
    Biochem Pharmacol; 2000 Nov 01; 60(9):1305-13. PubMed ID: 11008124
    [Abstract] [Full Text] [Related]

  • 15. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.
    DNA Repair (Amst); 2010 Jul 01; 9(7):745-53. PubMed ID: 20418188
    [Abstract] [Full Text] [Related]

  • 16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.
    Cell Physiol Biochem; 2016 Jul 01; 39(1):242-52. PubMed ID: 27336949
    [Abstract] [Full Text] [Related]

  • 17. Increased γ-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin.
    Adam-Zahir S, Plowman PN, Bourton EC, Sharif F, Parris CN.
    Chemotherapy; 2014 Jul 01; 60(5-6):310-20. PubMed ID: 26138778
    [Abstract] [Full Text] [Related]

  • 18. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
    Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT.
    Mol Cancer Ther; 2012 Nov 01; 11(11):2483-94. PubMed ID: 22914438
    [Abstract] [Full Text] [Related]

  • 19. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
    Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y, Reed E.
    Int J Oncol; 2013 Sep 01; 43(3):721-8. PubMed ID: 23817665
    [Abstract] [Full Text] [Related]

  • 20. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J, Zhu JY, Liu YB, Fu K, Tian Y, Li PY, Yang WQ, Yang SY, Yin JY, Yin G, Zhang Y.
    Gynecol Oncol; 2018 May 01; 149(2):341-349. PubMed ID: 29572031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.